Nasal cavity carcinoma

Summary

Nasal cavity carcinoma (MONDO:0003212) is a cancer and 8 clinical trials. Top therapeutic interventions include docetaxel anhydrous, cisplatin, and hydroxyurea. A subtype of nasal cavity cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 8

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	nasal cavity carcinoma
Mondo ID	MONDO:0003212
DOID	DOID:4931
NCIT	C9336
SNOMED CT	448990005
UMLS	C1377785
MedGen	235119
Anatomy (UBERON)	UBERON:0001707
Is cancer (heuristic)	yes

Also known as: cancer of nasal cavity · cancer of the nasal cavity · carcinoma of nasal cavity · carcinoma of the nasal cavity · nasal cavity cancer · nasal cavity carcinoma

Disease family

This is a subtype of nasal cavity cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › respiratory system cancer › nasal cavity cancer › nasal cavity carcinoma

Related subtypes (2): nasal cavity olfactory neuroblastoma, nasal cavity lymphoma

Subtypes (4): nasal cavity adenocarcinoma, nasal cavity carcinoma in situ, carcinoma arising in nasal papillomatosis, nasal cavity squamous cell carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 8.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	5
Not specified	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00117572	PHASE3	COMPLETED	Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
NCT02834013	PHASE2	ACTIVE_NOT_RECRUITING	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT04870762	PHASE2	RECRUITING	Customized 3D Printed Oral Stents During Head and Neck Radiotherapy
NCT05075980	PHASE2	ACTIVE_NOT_RECRUITING	Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
NCT07063212	PHASE2	RECRUITING	A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
NCT05114707	PHASE2	UNKNOWN	Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal Sinuses
NCT02012699	Not specified	RECRUITING	Integrated Cancer Repository for Cancer Research
NCT05614375	Not specified	RECRUITING	Endoscopic Surgery in the Treatment of Soft Tissue Sarcoma in Nasal and Paranasal Sinus

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DOCETAXEL ANHYDROUS	4	3
CISPLATIN	4	2
HYDROXYUREA	4	1
SACITUZUMAB GOVITECAN	4	1
CHEMBL1510899	0	1